Latest Recombinant Vaccines Companies Update
Merck & Co. and Moderna: In October 2022, these giants formed a collaboration to develop and commercialize personalized cancer vaccines (PCV) leveraging mRNA-4157/V940. This marks a significant step towards personalized medicine in the vaccine landscape.
Pfizer Inc. and BioNTech:In January 2022, they entered an agreement to develop the first mRNA-based Shingles vaccine. This innovative approach could offer better protection against Shingles compared to traditional vaccines.
Novartis AG:Novartis continues to invest heavily in its recombinant vaccine portfolio, particularly for emerging markets. Their efforts to develop affordable vaccines for diseases like Dengue and RSV hold immense potential for global health impact.
Sanofi:Sanofi is actively involved in developing recombinant vaccines for various diseases, including COVID-19 boosters and vaccines for respiratory syncytial virus (RSV). Their recent approval in Europe for a new recombinant shingles vaccine showcases their commitment to this market.
List of Recombinant Vaccines Key Companies in the Market
- Abiomed
- Emergent BioSolutions, Inc.
- GlaxoSmithKline
- Johnson & Johnson
- Sanofi Pasteur SA
- Serum Institute of India Pvt. Ltd
- Mitsubishi Tanabe Pharma Corporation
- Daiichi Sankyo
- Pfizer, Inc.